Visual compatibility of argatroban with selected drugs

Hartman, Christian; Baroletti, Steven; Churchill, William; Patel, Punit

doi:10.1093/ajhp/59.18.1784

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To ensure proper patient care in that setting, we investigated the physical and chemical compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration. The compatibility of argatroban with a variety of drugs used in the operative and cardiovascular arenas has been reported 8,9 ; however, GP IIb/IIIa-receptor antagonists were not among the drugs evaluated.…”

Section: Discussionmentioning

confidence: 99%

Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration

Patel

Hursting

2005

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration

Patel

Hursting

2005

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

show abstract

Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units

Kanji

Lam

Johanson

et al. 2010

Critical Care Medicine

View full text Add to dashboard Cite

Physical compatibility studies that provide the basis for y-site compatibility are lacking for commonly used medications in intensive care unit patients and may contribute to unsafe medication practices. Furthermore, the heterogeneity in the methodology of these studies likely contributes to the common finding of conflicting data for specific combinations of drugs. Future studies should apply similar methodologic and reporting principles to be able to reproduce and compare outcomes both clinically and in the laboratory.

show abstract

Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor

LaMonte¹,

Brown²,

Hursting³

2005

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Argatroban, a direct thrombin inhibitor, effectively inhibits free and clot-bound thrombin without the need of a cofactor and exerts dose-dependent anticoagulant effects that are rapidly active and rapidly reversible (elimination half-life: 39-51 min). Argatroban provides predictable parenteral anticoagulation and is well tolerated with an acceptably low bleeding risk in a variety of clinical settings, including heparin-induced thrombocytopenia, acute ischemic stroke, percutaneous coronary intervention and hemodialysis. This review will discuss the clinical pharmacology and utility of argatroban; in particular, clinical trial experiences will be discussed in patients with, or at risk of, heparin-induced thrombocytopenia (where heparins must be avoided) including those requiring hemodialysis or percutaneous coronary intervention, and in patients with acute ischemic stroke (where heparins are not generally recommended).

show abstract

Visual compatibility of argatroban with selected drugs

Cited by 5 publications

References 0 publications

Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration

Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration

Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units

Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor

Contact Info

Product

Resources

About